APA (7th ed.) Citation

AT, P., M, P., E, S., N, M., W, S., L, M., . . . CV, F. (2022). Efavirenz Pharmacokinetics and Human Immunodeficiency Virus Type 1 (HIV-1) Viral Suppression Among Patients Receiving Tuberculosis Treatment Containing Daily High-Dose Rifapentine. Clinical infectious diseases : an official publication of the Infectious Diseases Society of America, 75(4), 560. https://doi.org/10.1093/cid/ciab1037

Chicago Style (17th ed.) Citation

AT, Podany, et al. "Efavirenz Pharmacokinetics and Human Immunodeficiency Virus Type 1 (HIV-1) Viral Suppression Among Patients Receiving Tuberculosis Treatment Containing Daily High-Dose Rifapentine." Clinical Infectious Diseases : An Official Publication of the Infectious Diseases Society of America 75, no. 4 (2022): 560. https://doi.org/10.1093/cid/ciab1037.

MLA (9th ed.) Citation

AT, Podany, et al. "Efavirenz Pharmacokinetics and Human Immunodeficiency Virus Type 1 (HIV-1) Viral Suppression Among Patients Receiving Tuberculosis Treatment Containing Daily High-Dose Rifapentine." Clinical Infectious Diseases : An Official Publication of the Infectious Diseases Society of America, vol. 75, no. 4, 2022, p. 560, https://doi.org/10.1093/cid/ciab1037.